Ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of HKI-272 [neratinib] administered orally to healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer; Early breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Puma Biotechnology
- 11 May 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 11 May 2012 Actual patient number 56 added as reported by ClinicalTrials.gov.
- 11 Dec 2006 Status change